Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant versus physician's choice adjuvant endocrine monotherapy in ER-positive, HER2-negative early breast cancer
NL-OMON55972Phase 3Recruiting
- Sponsor
- Roche
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer and estrogen receptor-positive breast cancer (2 arms), sponsored by Roche. Primary endpoint: Invasive disease-free survival. Started Aug 2022; status: recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on NL-OMON55972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55972.